StockNews.AI
APDN
StockNews.AI
82 days

Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025

1. Applied DNA announces a 1-for-15 reverse stock split effective June 2, 2025. 2. Outstanding shares will decrease from 7.8 million to 519 thousand. 3. The move aims to comply with Nasdaq's $1.00 minimum bid requirement. 4. No fractional shares will be issued; existing shares will be adjusted. 5. Forward-looking statements highlight risks, including financial stability and market demand.

8m saved
Insight
Article

FAQ

Why Bearish?

Historically, reverse stock splits can signal company distress, negatively affecting investor sentiment.

How important is it?

The reverse stock split directly affects share structure, influencing investor confidence and trading dynamics.

Why Short Term?

Immediate impact expected due to compliance issues and market perception; potential long-term recovery depends on execution.

Related Companies

NASDAQ:APDNNASDAQ:ABCLNASDAQ:SRNE
Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 2, 2025, and Applied DNA common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (the "Nasdaq") as of the commencement of market open that same day.Applied DNA common stock will continue to trade on The Nasdaq Capital Market under the symbol "APDN" following the reverse stock split, with a new CUSIP number of 03815U607. The CUSIP number for the Company's book entry warrants will not change.After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced from approximately 7.8 million (as of the date of this press release) to approximately 519 thousand. The total authorized number of shares will not be reduced. Proportional adjustments will be made to the number of shares of common stock issuable upon exercise or vesting of the Company's outstanding stock options, restricted stock units, and warrants, as well as the applicable exercise or conversion prices, and to the number of shares issuable under the Company's equity incentive plans and other existing agreements. No fractional shares will be issued in connection with the reverse stock split, and fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share. There will be no change in the par value of $0.001 per share of the common stock as a result of the reverse stock split.As previously disclosed, at an annual meeting of stockholders held on May 22, 2025, the Company's stockholders voted to approve a proposal granting the Company's Board of Directors the discretion to amend the Company's certificate of incorporation to effect a reverse stock split of the Company's common stock at a ratio in the range from one-for-five to one-for-fifty. The Company's Board of Directors approved a 1-for-15 reverse stock split on May 27, 2025. The reverse stock split is primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining its listing on Nasdaq. There is no guarantee that the Company will meet the minimum bid price requirement, and even if it does, there is no guarantee that it will be able to meet all additional requirements for continued listing on Nasdaq.Applied DNA's transfer agent, Equiniti Trust Company, will provide information to stockholders regarding their stock ownership following the reverse stock split. Stockholders holding their shares in book-entry form or through a bank, broker, or other nominee do not need to take any action in connection with the reverse stock split. Their accounts will be automatically adjusted to reflect the number of shares owned. Beneficial holders are encouraged to contact their bank, broker, or other nominee with any procedural questions.About Applied DNA SciencesApplied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services.Visit adnas.com for more information. Follow us on X and LinkedIn.Forward-Looking StatementsThe statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding the effective date of the reverse stock split and the trading of the common stock on a split-adjusted basis, the Company's ability to timely implement the reverse stock split, the Company's belief that the reverse stock split will allow the Company to regain compliance with Nasdaq listing standards, its goal to position the company for long term-growth and value creation, and the potential to achieve that goal, and regarding the future success of its LineaDNA™ and LineaIVT™ platforms. Actual results could differ materially from those projected due to the Company's history of net losses, limited financial resources, substantial doubt regarding its ability to continue as a going concern, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our LineaDNA and/or LineaIVT platforms, the fact that there has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or LineaIVT platforms, the unknown amount of revenues and profits that will result from its clinical laboratory testing services, as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Reports on Form 10-Q filed on February 13, 2025, and May 15, 2025, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.Applied DNA Sciences Contact:Investor Relations contact: Sanjay M. Hurry, 917-733-5573, [email protected]Web: https://investors.adnas.com/###SOURCE: Applied DNA Sciences, Inc.

Related News